Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ

J Natl Cancer Inst. 2015 Sep 30;107(12):djv263. doi: 10.1093/jnci/djv263. Print 2015 Dec.

Abstract

Background: Impact of contemporary treatment of pre-invasive breast cancer (ductal carcinoma in situ [DCIS]) on long-term outcomes remains poorly defined. We aimed to evaluate national treatment trends for DCIS and to determine their impact on disease-specific (DSS) and overall survival (OS).

Methods: The Surveillance, Epidemiology, and End Results (SEER) registry was queried for patients diagnosed with DCIS from 1991 to 2010. Treatment pattern trends were analyzed using Cochran-Armitage trend test. Survival analyses were performed using inverse probability weights (IPW)-adjusted competing risk analyses for DSS and Cox proportional hazard regression for OS. All tests performed were two-sided.

Results: One hundred twenty-one thousand and eighty DCIS patients were identified. The greatest proportion of patients was treated with lumpectomy and radiation therapy (43.0%), followed by lumpectomy alone (26.5%) and unilateral (23.8%) or bilateral mastectomy (4.5%) with significant shifts over time. The rate of sentinel lymph node biopsy increased from 9.7% to 67.1% for mastectomy and from 1.4% to 17.8% for lumpectomy. Compared with mastectomy, OS was higher for lumpectomy with radiation (hazard ratio [HR] = 0.79, 95% confidence interval [CI] = 0.76 to 0.83, P < .001) and lower for lumpectomy alone (HR = 1.17, 95% CI = 1.13 to 1.23, P < .001). IPW-adjusted ten-year DSS was highest in lumpectomy with XRT (98.9%), followed by mastectomy (98.5%), and lumpectomy alone (98.4%).

Conclusions: We identified substantial shifts in treatment patterns for DCIS from 1991 to 2010. When outcomes between locoregional treatment options were compared, we observed greater differences in OS than DSS, likely reflecting both a prevailing patient selection bias as well as clinically negligible differences in breast cancer outcomes between groups.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / analysis
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / ethnology
  • Breast Neoplasms / mortality*
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Carcinoma, Intraductal, Noninfiltrating / chemistry
  • Carcinoma, Intraductal, Noninfiltrating / ethnology
  • Carcinoma, Intraductal, Noninfiltrating / mortality*
  • Carcinoma, Intraductal, Noninfiltrating / pathology
  • Carcinoma, Intraductal, Noninfiltrating / therapy*
  • Confounding Factors, Epidemiologic
  • Disease-Free Survival
  • Female
  • Humans
  • Mastectomy / methods
  • Mastectomy / statistics & numerical data*
  • Mastectomy, Modified Radical / statistics & numerical data
  • Mastectomy, Segmental / statistics & numerical data
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Staging
  • Odds Ratio
  • Proportional Hazards Models
  • Radiotherapy, Adjuvant / statistics & numerical data*
  • Receptors, Estrogen / analysis
  • Receptors, Progesterone / analysis
  • SEER Program
  • Sentinel Lymph Node Biopsy* / statistics & numerical data
  • Sentinel Lymph Node Biopsy* / trends
  • Survival Analysis
  • Treatment Outcome
  • United States / epidemiology

Substances

  • Biomarkers, Tumor
  • Receptors, Estrogen
  • Receptors, Progesterone